Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa
04 mai 2023 03h00 HE
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...
Compass Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
26 avr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
RS BioTherapeutics Appoints Pharmaceutical and Consumer Products Veteran Curtis R. Rhine as Its Chief Financial Officer
17 avr. 2023 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., April 17, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Appoints Pharmaceutical Industry Veteran Dean Hart as Chief Executive Officer
10 avr. 2023 11h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., April 10, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa
05 avr. 2023 07h20 HE
|
Endogena
SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous...
IRBM Selected for Participation in National Chemical Biology Consortium
04 avr. 2023 03h00 HE
|
IRBM
ROME, April 04, 2023 (GLOBE NEWSWIRE) -- IRBM, a drug discovery and early development research institute and global contract research organization, announces that it is joining the Chemical Biology...
Global Cancer Vaccine Market to Generate USD 13.4 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
23 mars 2023 09h00 HE
|
Next Move Strategy Consulting
New York, March 23, 2023 (GLOBE NEWSWIRE) -- According to a report published by Next Move Strategy Consulting, the global Cancer Vaccine Market generated USD 5.75 billion in 2022 and is projected to...
AL Amyloidosis Therapeutics Market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion | Future Market Insights, Inc.
20 mars 2023 06h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- The global AL amyloidosis therapeutics market is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth...
Culture Biosciences Focuses Technology and Service Platform on Biologics
14 mars 2023 08h00 HE
|
Culture Biosciences
San Francisco, March 14, 2023 (GLOBE NEWSWIRE) -- SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) – Culture Biosciences today announced that it is increasing its focus on upstream bioprocess...
Invasive Fungal Infection Therapeutics Market Size Worth US$ 10.36 billion With CAGR of 4.10% from 2022 to 2030
10 mars 2023 02h30 HE
|
Growth Plus Reports
Newark, New Castle, USA, March 10, 2023 (GLOBE NEWSWIRE) -- Invasive Fungal Infection Therapeutics Market Size Worth US$ 10.36 billion With CAGR of 4.10% from 2022 to 2030 As per the report...